Anthony Glover Mbbs,, Fracs

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7545570/publications.pdf

Version: 2024-02-01

| 56 | 912 | 430874 | 477307 |
|----------|----------------|--------------|----------------|
| papers | citations | h-index | g-index |
| | | | |
| 57 | 57 | 57 | 1363 |
| all docs | docs citations | times ranked | citing authors |

| # | Article | IF | Citations |
|----|--|----------------|-------------------------|
| 1 | MicroRNAâ€222 and MicroRNAâ€146b are tissue and circulating biomarkers of recurrent papillary thyroid cancer. Cancer, 2013, 119, 4358-4365. | 4.1 | 135 |
| 2 | microRNA-7 as a tumor suppressor and novel therapeutic for adrenocortical carcinoma. Oncotarget, 2015, 6, 36675-36688. | 1.8 | 79 |
| 3 | International Medullary Thyroid Carcinoma Grading System: A Validated Grading System for Medullary Thyroid Carcinoma. Journal of Clinical Oncology, 2022, 40, 96-104. | 1.6 | 57 |
| 4 | Long noncoding RNA profiles of adrenocortical cancer can be used to predict recurrence. Endocrine-Related Cancer, 2015, 22, 99-109. | 3.1 | 51 |
| 5 | Surgery alone for papillary thyroid microcarcinoma is less costly and more effective than long term active surveillance. Surgery, 2020, 167, 110-116. | 1.9 | 47 |
| 6 | A Proposed Grading Scheme for Medullary Thyroid Carcinoma Based on Proliferative Activity (Ki-67) Tj ETQq0 0 0 0 | rgBT /C 3.7 | Overlock 10 Tf 50 46 |
| 7 | MicroRNA Expression Profiles in the Management of Papillary Thyroid Cancer. Oncologist, 2014, 19, 1141-1147. | 3.7 | 39 |
| 8 | Molecular Markers Guiding Thyroid Cancer Management. Cancers, 2020, 12, 2164. | 3.7 | 34 |
| 9 | Thyroid cancer in the age of COVID-19. Endocrine-Related Cancer, 2020, 27, R407-R416. | 3.1 | 32 |
| 10 | Use of the Nerve Integrity Monitor during Thyroid Surgery Aids Identification of the External Branch of the Superior Laryngeal Nerve. Annals of Surgical Oncology, 2015, 22, 1768-1773. | 1.5 | 30 |
| 11 | Risk of needing completion thyroidectomy for lowâ€risk papillary thyroid cancers treated by lobectomy. BJS Open, 2019, 3, 299-304. | 1.7 | 29 |
| 12 | Current management options for recurrent adrenocortical carcinoma. OncoTargets and Therapy, 2013, 6, 635. | 2.0 | 23 |
| 13 | The pros and cons of prophylactic central neck dissection in papillary thyroid carcinoma. Gland Surgery, 2013, 2, 196-205. | 1.1 | 21 |
| 14 | Improving Outcomes in Adrenocortical Cancer: An Australian Perspective. Annals of Surgical Oncology, 2015, 22, 2309-2316. | 1.5 | 20 |
| 15 | Outcomes of routine ilioinguinal lymph node dissection for palpable inguinal melanoma nodal metastasis. British Journal of Surgery, 2014, 101, 811-819. | 0.3 | 19 |
| 16 | Immunohistochemical Validation of Overexpressed Genes Identified by Global Expression Microarrays in Adrenocortical Carcinoma Reveals Potential Predictive and Prognostic Biomarkers. Oncologist, 2015, 20, 247-256. | 3.7 | 19 |
| 17 | microRNA-431 as a Chemosensitizer and Potentiator of Drug Activity in Adrenocortical Carcinoma. Oncologist, 2019, 24, e241-e250. | 3.7 | 19 |
| 18 | Early postoperative stimulated serum thyroglobulin quantifies risk of recurrence in papillary thyroid cancer. Surgery, 2020, 167, 40-45. | 1.9 | 19 |

| # | Article | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | Incidence and Risk Factors for Occult Level 3 Lymph Node Metastases in Papillary Thyroid Cancer. Annals of Surgical Oncology, 2016, 23, 3587-3592. | 1.5 | 18 |
| 20 | Prospective evaluation of the utility of routine neuromonitoring for an established thyroid surgical practice. ANZ Journal of Surgery, 2017, 87, E138-E142. | 0.7 | 18 |
| 21 | Key MicroRNA's and Their Targetome in Adrenocortical Cancer. Cancers, 2020, 12, 2198. | 3.7 | 15 |
| 22 | Prophylactic central lymph node dissection informs the decision of radioactive iodine ablation in papillary thyroid cancer. American Journal of Surgery, 2021, 221, 886-892. | 1.8 | 15 |
| 23 | Factors That Inform Individual Decision Making Between Active Surveillance, Hemithyroidectomy and Total Thyroidectomy for Low-Risk Thyroid Cancer: A Scoping Review. Thyroid, 2022, 32, 807-818. | 4.5 | 15 |
| 24 | Delays to Low-risk Thyroid Cancer Treatment During COVID-19—Refocusing From What Has Been Lost to What May Be Learned and Gained. JAMA Otolaryngology - Head and Neck Surgery, 2021, 147, 5. | 2.2 | 13 |
| 25 | The Weight of the Resected Gland Predicts Rate of Success After Imageâ€Guided Focused Parathyroidectomy. World Journal of Surgery, 2015, 39, 1922-1927. | 1.6 | 12 |
| 26 | The Covidien LigaSure Maryland Jaw Device. Expert Review of Medical Devices, 2015, 12, 151-155. | 2.8 | 9 |
| 27 | Reciprocal interplay of miR-497 and MALAT1 promotes tumourigenesis of adrenocortical cancer. Endocrine-Related Cancer, 2019, 26, 677-688. | 3.1 | 9 |
| 28 | Utility of the American College of Surgeons National Surgical Quality Improvement Program surgical risk calculator in predicting mortality in an Australian acute surgical unit. ANZ Journal of Surgery, 2020, 90, 746-751. | 0.7 | 7 |
| 29 | The Significance of Histologically "Large Normal―Parathyroid Glands in Primary Hyperparathyroidism. World Journal of Surgery, 2020, 44, 1149-1155. | 1.6 | 6 |
| 30 | Multimodality Treatment Improves Locoregional Control, Progression-Free and Overall Survival in Patients with Anaplastic Thyroid Cancer: A Retrospective Cohort Study Comparing Oncological Outcomes and Morbidity between Multimodality Treatment and Limited Treatment. Annals of Surgical Oncology, 2021, 28, 7520-7530. | 1.5 | 6 |
| 31 | Focused parathyroidectomy without intraoperative parathyroid hormone measurement in primary hyperparathyroidism: Still a valid approach?. Surgery, 2021, 170, 1383-1388. | 1.9 | 6 |
| 32 | What is the Accuracy of the ACS-NSQIP Surgical Risk Calculator in Emergency Abdominal Surgery? A Meta-Analysis. Journal of Surgical Research, 2021, 268, 300-307. | 1.6 | 6 |
| 33 | Thermal sealing systems with and without tissue divider for total thyroidectomy. ANZ Journal of Surgery, 2014, 84, 383-385. | 0.7 | 5 |
| 34 | Epigenetic regulation of RET receptor tyrosine kinase and non-coding RNAs in MTC. Molecular and Cellular Endocrinology, 2018, 469, 48-53. | 3.2 | 5 |
| 35 | Outcomes of AdvancedÂMedullary Thyroid Carcinoma in the Era of Targeted Therapy. Annals of Surgical Oncology, 2022, 29, 64-71. | 1.5 | 5 |
| 36 | Treatment and management of adrenal cancer in a specialized Australian endocrine surgical unit: approaches, outcomes and lessons learnt. ANZ Journal of Surgery, 2019, 89, 48-52. | 0.7 | 4 |

| # | Article | IF | Citations |
|----|---|-----|-----------|
| 37 | The PanSurgâ€PREDICT Study: Endocrine Surgery During the COVIDâ€19ÂPandemic. World Journal of Surgery, 2021, 45, 2315-2324. | 1.6 | 4 |
| 38 | Thyroid cancer clinicians' views and experiences of delayed treatment during the <scp>COVID</scp> â€19 pandemic: An international crossâ€sectional survey. ANZ Journal of Surgery, 2021, 91, 2562-2564. | 0.7 | 4 |
| 39 | Sclerosing mesenteritis: a diagnosis worth considering. ANZ Journal of Surgery, 2015, 85, 291-292. | 0.7 | 2 |
| 40 | Pros and cons of hemiâ€thyroidectomy for lowâ€risk differentiated thyroid cancer. ANZ Journal of Surgery, 2021, 91, 1704-1710. | 0.7 | 2 |
| 41 | Thyroidectomy in Australia 2022: lessons from 21,000 consecutive cases. ANZ Journal of Surgery, 2022, 92, 1626-1630. | 0.7 | 2 |
| 42 | Best practice for the management of pediatric thyroid cancer. Expert Review of Endocrinology and Metabolism, 2014, 9, 175-182. | 2.4 | 1 |
| 43 | Impact of the American Thyroid Association guidelines on the Australian surgical management of papillary thyroid cancer. ANZ Journal of Surgery, 2018, 88, 1102-1103. | 0.7 | 1 |
| 44 | Change in Practice of Radioactive Iodine Administration in Differentiated Thyroid Cancer: A Single-Centre Experience. European Thyroid Journal, 2021, 10, 408-415. | 2.4 | 1 |
| 45 | Frozen section for intra-operative detection of nodal metastatic disease in breast cancer. Breast, 2010, 19, 148-149. | 2.2 | O |
| 46 | Is there an accurate biomarker test for thyroid cancer recurrence on the horizon?. International Journal of Endocrine Oncology, 2014, 1 , 3 -5. | 0.4 | 0 |
| 47 | Recurrent hyperaldosteronism after adrenalectomy: an indication for careful radiologic and histologic reâ€evaluation. ANZ Journal of Surgery, 2015, 85, 289-290. | 0.7 | O |
| 48 | Could miRNA replacement be a novel therapy for adrenocortical carcinoma?. International Journal of Endocrine Oncology, 2016, 3, 67-76. | 0.4 | 0 |
| 49 | Editorial - Endocrine Tumor. Molecular and Cellular Endocrinology, 2018, 469, 1-2. | 3.2 | O |
| 50 | Letter to the Editor: Reoperation for Bleeding After Thyroid and Parathyroid Surgery: Incidence, Risk Factors, Prevention, and Management. World Journal of Surgery, 2020, 44, 2441-2442. | 1.6 | 0 |
| 51 | Predicting distant metastatic disease in differentiated thyroid cancer: a matched case–control study. ANZ Journal of Surgery, 2021, 91, 716-723. | 0.7 | O |
| 52 | An unusual case of a penetrating neck injury (PNI) illustrating the use of a "no zone―approach for the management of this injury and a review of the literature. Trauma Case Reports, 2021, 32, 100402. | 0.4 | 0 |
| 53 | Abstract B04: The long noncoding RNA - PRINS as a novel recurrence biomarker and tumor suppressor for adrenocortical carcinoma. , 2016, , . | | O |
| 54 | ASO Author Reflections: Medullary Thyroid Cancerâ€"Establishing Treatment Paradigms in a Rapidly Evolving Therapeutic Landscape. Annals of Surgical Oncology, 2021, 29, 72. | 1.5 | 0 |

| # | Article | lF | CITATIONS |
|----|--|-----|-----------|
| 55 | ASO Visual Abstract: Outcomes of Advanced MTC in the Era of Targeted Therapy. Annals of Surgical Oncology, 2021, , 1. | 1.5 | 0 |
| 56 | Applying the  three buckets' theory of situational awareness to surgical training: an updated framework. ANZ Journal of Surgery, 2022, , . | 0.7 | 0 |